BioDuro-Sundia acquires drug product manufacturing facility
Irvine, CA, location will house 40,000 square feet of oral solid dosage forms
BioDuro-Sundia, a drug discovery and development services organization, has purchased a 40,000 square-foot commercial oral solid dose manufacturing facility in Irvine, CA. The contract research, development and manufacturing organization (CRDMO) is expecting commercial service operations at the site to begin on Jan. 1, 2022.
Features of the new facility include a yearly capacity of more than one billion units in tableting and encapsulation, along with aqueous and organic solvent process for fluid bed and coating capabilities.
BioDuro-Sundia is making new equipment investments in support of the commercial operation, including commercial spray drying capacity up to 100 kg/hr and hot melt extrusion capacity up to 30 kg/hr. These features offer a commercial extension to the company’s current oral solid development and manufacturing capabilities.
“This fully-audited and operational facility allows us to immediately support our clients who require larger scale commercial production,” says Kent Payne, president, development and manufacturing, US/EU, at BioDuro-Sundia.
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
